Related Experiment Videos
Repair of DNA containing O6-alkylguanine
1Department of Cellular and Molecular Physiology, Milton S. Hershey Medical Center, Pennsylvania State University College of Medicine, Hershey 17033.
Abstract:
O6-Alkylguanines, important DNA adducts formed by alkylating agents, can lead to mutations and to cell death unless repaired. The major pathway of repair involves the transfer of the alkyl group from the DNA to a cysteine acceptor site in the protein O6-alkylguanine-DNA alkyltransferase. The alkyltransferase brings about this transfer without need for cofactors and the DNA is restored completely by the action of a single protein, but the cysteine acceptor site is not regenerated and the number of O6-alkylguanines that can be repaired is equal to the number of active alkyltransferase molecules. The alkylated form of the protein is unstable in mammalian cells and is degraded rapidly. Cloning of the cDNAs for the alkyltransferase proteins from bacteria, yeast, and mammals indicates a significant similarity, particularly in the region surrounding the cysteine acceptor site. There is a major difference in the regulation of the alkyltransferase between mammalian cells and certain bacteria, where it is induced as part of the adaptive response to alkylating agents. Regulation of the content of alkyltransferase in mammalian cells differs with species and cell type and, in some cases, the level of the protein is increased by exposure to alkylating agents or X rays. A significant fraction of human tumor cell lines do not express the alkyltransferase gene and, thus, are much more sensitive to mutagenesis and killing by alkylating agents. The frequency of primary tumor cells that lack alkyltransferase protein is not yet clear. However, it is known that the level of alkyltransferase in tumors is a significant factor in resistance to both methylating agents and bifunctional chloroethylating agents. Inactivation of the alkyltransferase, which can be brought about by pretreatment with an alkylating agent or by exposure to O6-benzylguanine (a powerful nontoxic inhibitor), sensitizes tumor cells to these chemotherapeutic alkylating agents and may prove a useful therapeutic strategy.
Insights
DNA repair protein O6-alkylguanine-DNA alkyltransferase removes harmful O6-alkylguanines. Its inactivation sensitizes tumor cells to chemotherapy, offering a potential therapeutic strategy.
Area of Science:
- Molecular Biology
- DNA Repair Mechanisms
- Cancer Therapeutics
Background:
- O6-alkylguanines are DNA adducts formed by alkylating agents, potentially causing mutations and cell death.
- O6-alkylguanine-DNA alkyltransferase (AGT) is a key protein that repairs these adducts via direct alkyl group transfer.
- The AGT protein is consumed in the repair process and its alkylated form is rapidly degraded in mammalian cells.
Purpose of the Study:
- To review the mechanism, regulation, and therapeutic implications of O6-alkylguanine-DNA alkyltransferase.
- To highlight the role of AGT in cellular resistance to alkylating agents.
- To explore strategies for sensitizing tumor cells to chemotherapy by targeting AGT.
Main Methods:
- Comparative analysis of AGT cDNA sequences from different species (bacteria, yeast, mammals).
- Review of studies on AGT expression and regulation in various cell types and under different conditions (e.g., exposure to alkylating agents, X rays).
- Examination of the impact of AGT levels on sensitivity to chemotherapeutic alkylating agents.
Main Results:
- AGT proteins share significant sequence similarity, especially around the cysteine acceptor site.
- AGT regulation differs between bacteria (adaptive response) and mammalian cells (species/cell-type specific).
- Loss of AGT expression in human tumor cells increases sensitivity to alkylating agents; AGT levels influence tumor resistance to chemotherapy.
Conclusions:
- AGT plays a critical role in protecting cells from alkylating agent-induced DNA damage.
- Inactivating AGT, through pretreatment or inhibitors like O6-benzylguanine, can sensitize tumors to alkylating chemotherapeutics.
- Targeting AGT represents a promising strategy to enhance the efficacy of alkylating agent-based cancer therapy.